

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Broudy et al.

Serial No.: 09/352,466

Filed: July 13, 1999

For: Monoclonal Antibodies to Stem Cell Factor Receptors

Docket No.: A-195CDD



Group Art Unit No.: 1642

Examiner: L. Helms

RECEIVED

JAN 19 2001

TECH CENTER 1600/2000

RESPONSE TO OFFICE ACTIONAssistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to the Office Action dated August 30, 2000 in which Claims 1-25 were subject to a restriction requirement. Applicants hereby make a provisional election of the invention to be prosecuted.

REMARKSThe Restriction Requirement

The Examiner has required restriction to one of the following inventions under 35 U.S.C. 121:

- I. Claims 1-6 and 22-25, drawn to a monoclonal antibody and hybridoma
- II. Claims 7-10, drawn to a method of purifying hematopoietic cells
- III. Claim 11, drawn to a method of reconstituting hematopoietic cells
- IV. Claim 12, drawn to a method of gene therapy
- V. Claim 13, drawn to a method of separating normal cells from neoplastic leukemia cells
- VI. Claims 14-15, drawn to a method of treating leukemia cells
- VII. Claims 16-17, drawn to a method of treating solid tumors
- VIII. Claims 18-20, drawn to a method of determining the presence of SCF receptors in a cell

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

D. D. Miller  
Date

1/11/01  
Signature

RECEIVED

JAN 19 2001

TECH CENTER 1600/2900

IX. Claim 21, drawn to a method of modifying the sensitivity to cell cycle-specific chemotherapeutic agents

Applicants hereby elect with traverse the invention of Group IX corresponding to Claim 21. It is acknowledged that the non-elected claims are withdrawn from further consideration. No change of inventorship is required.

Supplemental Information Disclosure Statement

Applicants submit herewith a Supplemental Information Disclosure Statement and Form PTO-1449 and request that the references listed therein be considered and made of record in the present application.

**CONCLUSION**

Claim 21 is in condition for allowance and an early notice thereof is solicited.

Respectfully submitted,

Robert B. Winter  
Attorney/Agent for Applicant(s)  
Registration No.: 34,458  
Phone: (805) 447-2425  
Date:

Please send all future correspondence to:

U.S. Patent Operations/RBW  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799